Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07389525 · ClinicalTrials.gov registry record · Early Phase 1
Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study
A Early Phase 1 study, sponsored by Indiana University.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 80
- Enrollment target
NCT07389525 is a Early Phase 1 study that has not yet begun recruiting, run by Indiana University. The registered enrollment target is 80 participants.
The verdict
NCT07389525, a Early Phase 1 study, has not yet begun recruiting, sponsored by Indiana University.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
Immune checkpoint inhibitors (ICIs) (also called "immunotherapy") are an effective family of anti-cancer drugs, but they can cause serious side effects. Some evidence suggests these side effects might happen because ICIs interact with other drugs that you may already be taking, making those drugs work differently, or causing more side effects. The purpose of this study is to see whether ICIs impact how the liver processes other drugs. To do this, participants will be given a probe cocktail of 7 different FDA-approved drugs that are processed in different ways in the liver.
Interventions
- DRUG ICI Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07389525
The ClinicalTrials.gov registry entry for NCT07389525 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ICI Therapy is the first listed.
NCT07389525 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07389525 about?
NCT07389525 is a clinical study titled "Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study". Immune checkpoint inhibitors (ICIs) (also called "immunotherapy") are an effective family of anti-cancer drugs, but they can cause serious side effects. Some evidence suggests these side effects might happen because ICIs interact with other drugs that you may already be taking, making those drugs wo...
What is the current status of trial NCT07389525?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 80 participants. The study started on 2026-06. Estimated completion is 2027-12.
What interventions are being tested in trial NCT07389525?
The interventions under investigation include: ICI Therapy (DRUG).
Who is sponsoring clinical trial NCT07389525?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.